Accueil   Diary - News   All news Alizée Pharma

Alizée Pharma

 

Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The group is managed by a team of drug development experts and by a board of directors with a breadth of international experience. Its business strategy is to advance programs based on medical innovation to the clinical stage and establish partnerships with pharmaceutical companies to secure both short and long-term revenue streams. Since its creation the group has raised over €15 million from private and institutional investors and has acquired and implemented three programs in three companies:

• Alizé Pharma SAS is developing AZP-531, a stabilized analog of unacylated ghrelin, a physiological gastrointestinal peptide. This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and has completed Phase I for type 2 diabetes.

• Prior to its acquisition by a subsidiary of Jazz Pharmaceuticals plc in March 2016, Alizé Pharma II SAS was focused on the development of pegcrisantaspase (ASPAREC®), a new pegylated recombinant Lasparaginase in onco-hematological rare diseases.

• Alizé Pharma III SAS has acquired exclusive worldwide rights on a family of new peptides with bone anabolic properties, to be developed in osteoporosis and other bone diseases. This I-HBD1 program is at the lead optimization stage.

 

Alizé Pharma II, a company of the Alizé Pharma Group, acquired by Jazz Pharmaceuticals

 

Alizé Pharma II announces that a subsidiary of Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has acquired 100% of its shares. This all-cash transaction closed in March 2016. The deal is valued at up to €18 million, including an upfront payment of €8 million and potential payments of up to €10 million related to regulatory milestones. The transaction did not involve the transfer of any employees from the Alizé Pharma group to Jazz Pharmaceuticals.


Read the press release

 

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree